# Micafungin Salvage Mono-therapy in Invasive Aspergillosis

> **NCT00376337** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 17 (actual)

## Conditions studied

- Invasive Aspergillosis

## Interventions

- **DRUG:** Micafungin
- **DRUG:** Systemic antifungal therapy

## Key facts

- **NCT ID:** NCT00376337
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Study was stopped due to difficulties in recruitment and changes in standard care for invasive aspergillosis
- **Last updated:** 2013-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00376337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00376337, "Micafungin Salvage Mono-therapy in Invasive Aspergillosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00376337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*